Answers are grounded in this paper and cite their sources.
Staphylococcus aureus is a notorious pathogen distinguished by its robust capacity to form biofilms, a key factor for host immune evasion and antibiotic resistance. In the quest for novel antibiofilm agents, revisiting traditional medicinal knowledge – particularly plant-based therapies – offers a promising strategy. Myrica esculenta, an ethnomedicinal Himalayan plant, is widely used in folk medicine for treating respiratory, gastrointestinal disorders, wound care, and toothache. Although preliminary studies on the antibacterial activity of its bark extract against S. aureus have been reported, its antibiofilm potential remains unexplored. In this study, six solvents were systematically evaluated for extraction efficiency from M. esculenta bark, with methanol yielding the highest metabolite recovery (33.79%) and exhibiting strong antibacterial activity with MIC of 1 mg/mL. The extract significantly inhibited biofilm initiation and disrupted mature biofilms of S. aureus (Newman) in a dose-dependent manner (MIC to 4 × MIC), accompanied by reduced exopolysaccharide production and decreased surface colonization. GC-MS analysis identified eight bioactive compounds, while molecular docking with the aggregation‐prone region of the biofilm-associated protein (Bap) revealed strong binding affinities for key constituents. Additionally, membrane damage and bactericidal effects were confirmed. Toxicity assessment revealed no toxicity to HEK-293 mammalian cells, highlighting its safe therapeutic potential.
No takes yet. Share an insight, caveat, or question.
Ezung et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: